Andere talen EyePoint Pharmaceuticals, Inc.

Aandelen

EYPT

US30233G2093

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 17-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
20,94 ^USD	-4,12%		-8,52%	-9,39%

02/04	EyePoint Pharmaceuticals, Inc. Breidt wetenschappelijke adviesraad uit	CI
07/03	Sectorupdate: Gezondheidszorgaandelen gemengd voor de beurs op donderdag	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	17/04
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	16/04
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists	02/04
EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board	02/04
EyePoint Pharmaceuticals : Investor Presentation March 2024	22/03
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	18/03
EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index	18/03
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	07/03
EyePoint Pharmaceuticals' Q4 Net Loss Narrows, Revenue Advances; Shares Up Pre-Bell	07/03
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q4 Revenue $14M	07/03
EyePoint Pharmaceuticals: Q4 Earnings Snapshot	07/03
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments	07/03
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
North American Morning Briefing : Powell Still in -2-	07/03
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer	04/03
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer	04/03
EyePoint Pharmaceuticals, Inc. Announces Executive Changes	04/03
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024	29/02
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences	27/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen EyePoint Pharmaceuticals, Inc.

Aandelen

EYPT

US30233G2093

Andere talen

Filters